Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.
A group of researchers from Israel and the US report that they have characterized chromosomal abnormalities in different colorectal cancer stages and identified alterations associated with poor outcomes.
Both the project and the service are designed to offer cancer patients detailed information about their tumor at a timescale that can help their physicians tailor treatments. However, some experts say the results will not benefit many patients today.